Galectin Therapeutic (GALT)

$3.06 0.31 (9.20%)

16:00 EDT GALT Stock Quote Delayed 30 Minutes

GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023

By InvestorPlace Earnings Apr 5, 2024

GALT stock results show that Galectin Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.

7 Short-Interest Stocks to Target for Explosive Gains

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Volume:

Previous Close -

Market Cap 181.75M

PE Ratio -19.13

EPS -0.16

Volume (Avg. Vol.) 305,544

Day's Range $2.88 - $3.29

52-Week Range $1.28 - $4.27

Dividend & Yield N/A (N/A)

GALT Stock Predictions, Articles, and Galectin Therapeutic News

From InvestorPlace
From the Web

GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring

By Chris MacDonald, InvestorPlace Contributor Jul 9, 2021

Today, a key announcement of some positive clinical trial data has sent investors in Galectin and GALT stock on a nice ride.

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Friday Morning

By William White, InvestorPlace Writer Apr 16, 2021

The weekend is almost here but investors have one more day of trading and we're helping out with the biggest pre-market movers for Friday.

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning

By William White, InvestorPlace Writer Apr 14, 2021

We're at the midpoint of the week and InvestorPlace.com is taking a look at the biggest pre-market movers for investors to keep an eye on.

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning

By William White, InvestorPlace Writer Apr 7, 2021

We're only halfway through the week but there's plenty of pre-market movers that investors will want to keep an eye on today.

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

By Aaron Levitt, InvestorPlace Contributor Sep 26, 2018

Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.

5 Clinical-Stage Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor May 29, 2018

Clinical-stage biotech stocks offer plenty of promise to investors looking to take on some risk. Here are five to buy today.

25 Biotechnology Stocks to Buy Now

By Portfolio Grader Oct 3, 2016

25 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

Hottest Manufacturing Stocks Now – ARRY CHMT SMMT SELB

By Portfolio Grader Sep 26, 2016

The following stocks were moving the Manufacturing sector today.

Biggest Movers in Manufacturing Stocks Now – GALT CERC OVAS EBIO

By Portfolio Grader Sep 21, 2016

The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.

13 Biotechnology Stocks to Sell Now

By Portfolio Grader Jul 18, 2016

The ratings of 13 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

29 Biotechnology Stocks to Sell Now

By Portfolio Grader Jun 27, 2016

This week, the overall grades of 29 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

28 Biotechnology Stocks to Sell Now

By Portfolio Grader Jun 20, 2016

This week, the overall grades of 28 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

27 Biotechnology Stocks to Sell Now

By Portfolio Grader May 16, 2016

The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Biotech Stocks With Upside Target Ebola, Liver Disease

By Sep 16, 2014

Developing successful Ebola and liver disease treatments is an incredibly risky opportunity for biotech stocks to create value.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

From The Motley Fool Mar 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Galectin Therapeutic (GALT)

GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023

7 Short-Interest Stocks to Target for Explosive Gains

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Galectin Therapeutic (GALT)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

GALT Stock Predictions, Articles, and Galectin Therapeutic News

Subscriber Sign in